Summary This 4 year study reports on a pharmacokinetic study for the widely used regimen of cis-platin plus continuous 5-day 5-FU as first-line chemotherapy of head and neck cancer, and the benefit of such data for real-time therapy management. Pharmacokinetic analysis of 177 cycles for 77 patients from a group of 89 patients (group 1; 228 cycles) revealed that both the time-concentration product (AUC) for the entire cycle and the half-cycle AUC (AUCO3days) were predictive of cycle toxicity. Real-time analysis of individual AUCO-3 days was used to decide whether to reduce the dose during the second half of the cycle for a total of 249 cycles (81 patients; group 2). The dose in the second half of the course was reduced in 40% of the group 2 courses. There was a statistical difference in complete response rates between group 1 (31%) and group 2 (47%), (0.02<P<0.05) and a statistically significant reduction was observed in the incidence of toxic cycles (>grade 2, group 1= 20% versus group 2 = 12.4%; 0.02 <P <0.05). Pharmacokinetic follow-up of these patients has proved to be an objective means to improve therapeutic index significantly.
In addition to the digestive tract, where its efficacy remains limited (Buroker et al., 1985) , chemotherapy by 5-FU is used for other disease sites. In squamous cell carcinoma of the head and neck very high response rates have been observed when the drug is combined with cisplatin (CDDP) (Thyss et al., 1986b; Amrein & Weitzman, 1985; Kish et al., 1982) . This combination protocol is accompanied by a significant incidence of toxicity (Amrein & Weitzman, 1985) that is often acceptable but sometimes severe, depending on the dose (Merlano et al., 1987) or the specific site (Kies et al., 1987) .
One of the major objectives of clinical pharmacokinetics is to improve the therapeutic index on an individual patient basis. For a limited population of head and neck carcinoma patients treated by CDDP-5-FU, we previously showed that the digestive tract and/or haematological tolerance was linked to the degree of total body exposure to the drug during the cycle (C xT, area under curve, AUC) (Thyss et al., 1986a) .
The first part of the present study extends and confirms this result on a larger population. In the second stage, data obtained were used for a prospective study in an attempt to improve the therapeutic index. Chemotherapy regimen Treatment was as follows. Day 0, 6h hydration with 5% dextrose (2 litres), NaCl (6gl-1), and KCI (3gl-1), followed by CDDP (100mgm-2) 1 mgmin-1 i.v. in normal saline (0.5 litres) with 1.6% mannitol (0.25 litres), and then 5% dextrose (1 litre), NaCl (6gI-1) and KCI (3g -1). Days 1-5, (Thyss et al., 1987) and neurological toxicity (Weiss et al., 1974) , or without therapeutic consequences (alopoecia, cutaneous toxicity).
Subjects and methods

Study population
Pharmacokinetic analysis Two blood samples were collected every day (8 a.m., 5 p.m.) during each 5-FU course. Venous blood (5 ml) was drawn on EDTA tubes and samples were immediately brought to the laboratory and centrifuged (Omin, 2,500 r.p.m.). Plasma was stored at -200C until analysed (within 1-3 days). For group 2, the tubes corresponding to the first two days of 5-FU administration and the tube obtained at 8a.m. on the third day (first half of the 5-FU cycle) were all analysed on the morning of the third day to determine the half-cycle AUC (AUCO-3 days) and thus modify or not the second half-cycle Although there was some overlap in the data, the distributions were significantly different between toxic and non-toxic courses. Median values were respectively (ng ml-1h-) for non-toxic cycles: 5,500 (AUCO3 days) and 26,000 (AUCO5 days) and for toxic cycles: 11,000 (AUCO3 days) and 34,000 (AUCOsdays). We identified a threshold AUCO-3days value of 15,000ngml-Ph-1 that predicted cycle toxicity (X2=39.8, P<0.001). For definition of toxicity and response see Subjects and methods.
.vl Weitzman, 1985) . In this combination regimen, continuous 5-FU administration (Amrein & Weitzman, 1985) has improved haematological tolerance in comparison with bolus injections (Merlano et al., 1987) . Stomatitis remains the major toxicity with continuous 5-FU; the frequency was 21% in 131 treatment cycles reported by Amrein & Weitzman (1985) . Toxicity may lead to lengthening of the interval between cycles and to reduction in the total number of cycles scheduled. In both cases, the dose intensity is reduced. This might be expected to compromise the cytotoxic activity of a phase-specific drug such as 5-FU. Indeed, clinical experience has shown that the number of CDDP-5-FU cycles is of prime importance for the complete response rate and survival in advanced head and neck cancer (Rooney et al., 1984) . In these patients (Thyss et al., 1986b) , we previously found that the clinical response to CDDP-5-FU is a major prognostic factor. It is thus important not to shorten the chemotherapy programme because of excessive, unanticipated toxicity.
One of the ultimate goals in clinical pharmacokinetics of anticancer agents is effective improvement of the therapeutic index of treatments (Sulkes & Collins, 1987; Allen, 1983) . This 4-year study conducted on 170 patients receiving a total of 477 CDDP-5-FU cycles attains this goal and confirms our previous results (Thyss et al., 1986a) . This study involved two sequential stages: a retrospective pharmacokinetic analysis followed by a prospective evaluation. Tolerance to treatment was significantly improved. Haematological and/or digestive tract toxicity attributable to 5-FU was reduced from 20 to 12.4%. Moreover, although dose reduction was performed in 40% of cycles in group 2, the complete response rate was significantly higher than in group 1 (Table  II) . The proportion of advanced stages (T3, T4) was not significantly different, and thus cannot explain the difference in response rates between the two groups. In fact, due to a better tolerance in group 2, treatment compliance was greater than in group 1. It is likely that the difference in response rates may be due to a difference in treatment intensity between the two groups. It must be kept in mind that at the target level 5-FU by itself is not active and must be transformed into FUTP and FdUMP to be cytotoxic (Myers, 1981) . These key biochemical steps are thus decisive in the activity of the drug.
The possibility of giving more drug to a patient with a low AUC during the first half of the cycle could be justified pharmacologically. If mean values are considered, the AUC values of the first half of cycle were lower for nonresponders than for complete responders (Table I) . However, the high interpatient variability in this pharmacokinetic parameter prevented the drawing of statistically significant conclusions. This particular point merits re-evaluation on a larger group of patients. However, for patients with a very low AUCO3 days ( < 5,000 ng ml-h-), it might be advisable to increase the 5-FU dose for the second half of the cycle in order to obtain an increased chance of better response.
These results emphasise the role of drug AUC as one of the best pharmacokinetic parameters for predicting pharmacodynamic events (Powis, 1985) . HPLC is now widely used in most clinical biochemistry laboratories and 5-FU analysis can thus be easily performed on a routine basis to monitor treatment. The cost of our policy is evaluated in Appendix 2. We believe that pharmacokinetic follow-up of these patients is an objective means to improve their therapeutic index significantly.
Appendices
Appendix 1: Construction and use of Figure 2 The line has been determined as follows: 15,000 ng ml1h1 is the cut-off value separating significantly toxic from nontoxic cycles in group 1. This was the starting point for reducing or not the 5-FU dose for the second part of the cycle in group 2. We estimated that a 30% dose reduction (corresponding to 70% of the initial dose scheduled) would lead to an objective decrease in steady state blood 5-FU. On the other hand, above an AUCO3 days of 30,000 ng ml-h-I all cycles were toxic in group 1. This value is also close to the median of AUCO5 days for non-toxic cycles of group 1. Thus above this AUCO3 days threshold it was decided to stop giving 5-FU during the second part of the cycle in group 2. For a given patient, X, receiving 1.7 g 5-FU per day if AUCO3 days = 20,000 ng ml 1 h-1 at the third day of the cycle then the 5 FU dose will be changed to 0.77 g per day for the second part of the cycle (45% of the initial dose), in accordance with the figure found on the y-axis after the intercept with the line of the 20,000 value from the x-axis. For another patient, Y, receiving 1.8g per day and with an AUCO3 days of 10,000 ng ml-1h-1, the 5-FU dose delivered during the second part of the cycle will be the same 1.8 g per day because 10,000 ng ml1 h1 is below the x-axis threshold of 15,000ngml-1h-1. 
